Genentech Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive Lymphomas

Core Insights - Genentech announced new data on Lunsumio (mosunetuzumab-axgb) showcasing its potential in earlier treatment lines for lymphoma, presented at the 67th American Society of Hematology Annual Meeting [1] Group 1: Efficacy and Clinical Data - Lunsumio shows promise in combination with lenalidomide for relapsed or refractory follicular lymphoma, with a complete response rate of 87.0% in a Phase III study [2] - Long-term follow-up data from the Phase Ib/II GO40516 study indicated an overall response rate of 77.5% for Lunsumio plus Polivy in relapsed or refractory large B-cell lymphoma, compared to 50.0% for Rituxan plus Polivy [3] - Five-year follow-up data from the Phase II GO29781 study reported a 78.5% overall survival rate for intravenous Lunsumio in third-line or later follicular lymphoma [5] Group 2: Regulatory Status and Approvals - Lunsumio is approved in over 60 countries for patients with follicular lymphoma who have received at least two prior systemic therapies, with recent approval from the European Commission [6] - A decision from the US Food and Drug Administration regarding Lunsumio is expected soon [6] Group 3: Company Strategy and Commitment - Genentech is committed to exploring new formulations and combinations of Lunsumio and other bispecific antibodies to enhance patient experience and treatment options [7] - The company has been developing innovative treatments in hematology for over 20 years, focusing on improving outcomes for patients with blood diseases [49]